Ignite Creation Date:
2025-12-24 @ 11:37 PM
Ignite Modification Date:
2026-02-10 @ 1:55 AM
Study NCT ID:
NCT04201756
Status:
COMPLETED
Last Update Posted:
2022-12-23
First Post:
2019-12-04
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Neoadjuvant Afatinib Therapy for Potentially Resectable Stage III EGFR Mutation-Positive Lung Adenocarcinoma
Sponsor:
Shanghai Pulmonary Hospital, Shanghai, China
Organization:
Organization Data
Organization:
Class:
OTHER
Study ID:
1200.0328(TEAM, LungMate-004)
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
OTHER
Responsible Party:
Responsible Party Title:
Responsible Party Type:
PRINCIPAL_INVESTIGATOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None